Myelodysplasia and Transgene Inactivation in X-CGD-γ Retroviral Gene Therapy: The Usual Suspects and New Players
Overview
Overview
Journal
Mol Ther
Publisher
Cell Press
Specialties
Molecular Biology
Pharmacology
Pharmacology
Date
2023 Nov 19
PMID
37980903
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Salter J, Bennett R, Smith H
. The APOBEC Protein Family: United by Structure, Divergent in Function. Trends Biochem Sci. 2016; 41(7):578-594.
PMC: 4930407.
DOI: 10.1016/j.tibs.2016.05.001.
View
2.
Stein S, Ott M, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A
. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med. 2010; 16(2):198-204.
DOI: 10.1038/nm.2088.
View
3.
Wong R, Sackey S, Brown D, Senadheera S, Masiuk K, Quintos J
. Lentiviral gene therapy for X-linked chronic granulomatous disease recapitulates endogenous CYBB regulation and expression. Blood. 2022; 141(9):1007-1022.
PMC: 10163279.
DOI: 10.1182/blood.2022016074.
View
4.
Sobrino S, Magnani A, Semeraro M, Martignetti L, Cortal A, Denis A
. Severe hematopoietic stem cell inflammation compromises chronic granulomatous disease gene therapy. Cell Rep Med. 2023; 4(2):100919.
PMC: 9975109.
DOI: 10.1016/j.xcrm.2023.100919.
View
5.
Braun C, Boztug K, Paruzynski A, Witzel M, Schwarzer A, Rothe M
. Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity. Sci Transl Med. 2014; 6(227):227ra33.
DOI: 10.1126/scitranslmed.3007280.
View